ACADIA Pharmaceuticals initiates phase 3 pivotal study of trofinetide in Rett Syndrome

This article was originally published here

Rett syndrome is a serious and rare neurodevelopmental congenital CNS disorder with symptoms that typically present between six to 18 months of age, and lead to problems with

The post ACADIA Pharmaceuticals initiates phase 3 pivotal study of trofinetide in Rett Syndrome appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply